Early and late mortality in hospitalised patients with raised cardiac troponin T

Aims Cardiac troponins are measured in acute coronary syndrome (ACS) and other conditions. The authors investigate the prognostic significance of cardiac troponin T (TnT) test and comorbid medical conditions. Methods Consecutive patients admitted to the Aintree University Hospital, Liverpool, between 2 January 2004 and 29 February 2004 who had TnT measurement were included. Patients were separated into normal (<0.01 μg/l) or raised TnT levels (≥0.01 μg/l), and further categorised into: (1) normal TnT with unstable angina; (2) normal TnT with non-ACS; (3) raised TnT with ACS; and (4) raised TnT with non-ACS. Cox regression was used to identify prognostic variables, and logrank test to compare 7-year survival. Results Of 1021 patients, 313 had raised TnT (195 ACS, 118 non-ACS) and 708 normal TnT (80 ACS, 628 non-ACS). Age (HR 1.06; 95% CI 1.05 to 1.07), congestive cardiac failure (HR 1.37; 95% CI 1.11 to 1.69), cerebrovascular disease (HR 1.37; 95% CI 1.10 to 1.71), chronic obstructive airway disease (HR 1.44; 95% CI 1.19 to 1.75), liver disease (HR 4.16; 95% CI 2.37 to 7.31), renal disease (HR 1.83; 95% CI 1.27 to 2.64), tumour (HR 1.39; 95% CI 1.07 to 1.79), lymphoma (HR 4.81; 95% CI 2.07 to 11.16), metastatic cancer (HR 3.55; 95% CI 2.32 to 5.45) and a higher Charlson's comorbidity score (HR 1.20, 95% CI 1.13 to 1.26) were adverse predictors. Both raised TnT with ACS (HR 1.92, 95% CI 1.54 to 2.39) and raised TnT with non-ACS (HR 2.37, 95% CI 1.87 to 3.00) were associated with worse survival. Raised TnT with non-ACS had a worse survival than raised TnT with ACS (p=0.001). Conclusion Hospitalised patients with raised TnT levels from any cause predicted a higher mortality than normal TnT, with worst survival in those without an obvious ACS.

[1]  M. Sabatine,et al.  Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (T , 2010, American heart journal.

[2]  A. Hoes,et al.  Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal , 2010, Heart.

[3]  G. Lamas,et al.  Focused Update of the ACC / AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2007 .

[4]  R. Giugliano,et al.  Novel biomarkers in cardiovascular disease: update 2010. , 2010, American heart journal.

[5]  K. Alexander,et al.  Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. , 2011, American heart journal.

[6]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[7]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[8]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[9]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[10]  K. Eagle,et al.  Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events , 2010, Heart.

[11]  A. Jaffe,et al.  Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain - an evaluation with respect to the Universal Definition of Myocardial Infarction. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[12]  P Wong,et al.  Effects of comorbidity and hospital care on 6-month mortality in patients with elevated cardiac troponin T , 2007, Postgraduate Medical Journal.

[13]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[14]  Mario Plebani,et al.  Recommendations for the use of cardiac troponin measurement in acute cardiac care. , 2010, European heart journal.

[15]  A. Shah,et al.  The clinical relevance of raised cardiac troponin I in the absence of significant angiographic coronary artery disease. , 2005, International journal of cardiology.

[16]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[17]  R. Christenson,et al.  Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. , 2009, Clinical chemistry.

[18]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[19]  N. Brunetti,et al.  Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases. , 2008, Journal of interventional cardiology.

[20]  P Wong,et al.  Raised cardiac troponin T levels in patients without acute coronary syndrome , 2007, Postgraduate Medical Journal.